SCHEMBL1065199

SCHEMBL1065199

O=C(O)CCN(Cc1ccccn1)Cc1ccccn1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.68
TDP1 Q9NUW8 2/20 0.68
MAPT P10636 1/20 0.68
LIN28A Q9H9Z2 1/20 0.68
KMT2A Q03164 1/20 0.51
HDAC1 Q13547 3/20 0.49
HDAC3 O15379 1/20 0.49
HDAC4 P56524 1/20 0.49
HDAC7 Q8WUI4 1/20 0.49
HDAC2 Q92769 1/20 0.49
HDAC10 Q969S8 1/20 0.49
HDAC11 Q96DB2 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
HDAC9 Q9UKV0 1/20 0.49
HDAC5 Q9UQL6 1/20 0.49
KCNA5 P22460 1/20 0.49
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
CYP1A2 P05177 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19876816 0.97 SMN1; SMN2 (0.69) SMN1; SMN2TDP1MAPTLIN28AKMT2A
SCHEMBL22749407 0.94 SMN1; SMN2 (0.60) SMN1; SMN2TDP1MAPTLIN28AKMT2A
SCHEMBL23495444 0.91 SMN1; SMN2 (0.56) SMN1; SMN2TDP1MAPTLIN28AKMT2A
SCHEMBL5062633 0.90 SMN1; SMN2 (0.64) SMN1; SMN2TDP1MAPTLIN28AKMT2A
SCHEMBL12762776 0.89 SMN1; SMN2 (0.62) SMN1; SMN2TDP1MAPTLIN28AKMT2A
SCHEMBL7949662 0.88 SMN1; SMN2 (0.60) SMN1; SMN2TDP1MAPTLIN28AKMT2A
SCHEMBL1517940 0.88 SMN1; SMN2 (0.60) SMN1; SMN2TDP1MAPTLIN28AKMT2A
SCHEMBL19876826 0.85 TDP1 (0.71) SMN1; SMN2TDP1MAPTLIN28AKMT2A
SCHEMBL29574935 0.85 SMN1; SMN2 (0.71) SMN1; SMN2TDP1MAPTLIN28AKMT2A
SCHEMBL8200516 0.85 SMN1; SMN2 (0.71) SMN1; SMN2TDP1MAPTLIN28AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12625144-B2 Chemoselective sensitivity booster for tagging a peptide, peptide conjugate, or similar reactive molecule Indian Institute Of Science Education And Research Bhopal (IN) 2026-05-12 US disclosed
US-20220299521-A1 CHEMOSELECTIVE SENSITIVITY BOOSTER FOR TAGGING A PEPTIDE, PEPTIDE CONJUGATE, OR SIMILAR REACTIVE MOLECULE Indian Institute Of Science Education And Research Bhopal (IN) 2022-09-22 US disclosed
WO-2020245843-A1 CHEMOSELECTIVE SENSITIVITY BOOSTER FOR TAGGING A PEPTIDE, PEPTIDE CONJUGATE, OR SIMILAR REACTIVE MOLECULE Indian Institute Of Science Education And Research Bhopal (IN) 2020-12-10 WO disclosed
US-10039845-B2 Labeled inhibitors of prostate specific membrane antigen (PSMA) biological evaluation, and use of imaging agents THE JOHNS HOPKINS UNIVERSITY (US) 2018-08-07 US disclosed
US-20180085478-A1 LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) BIOLOGICAL EVALUATION, AND USE OF IMAGING AGENTS THE JOHNS HOPKINS UNIVERSITY (US) 2018-03-29 US disclosed
US-9694091-B2 Labeled inhibitors of prostate specific membrane antigen (PSMA) biological evaluation, and use of imaging agents THE JOHNS HOPKINS UNIVERSITY (US) 2017-07-04 US disclosed
EP-2963017-A1 TECHNETIUM-DIPYRIDINE COMPLEXES, AND METHODS OF USE THEREOF Molecular Insight Pharmaceuticals, Inc. (US) 2016-01-06 EP disclosed
EP-1482985-B1 TECHNETIUM-DIPYRIDINE COMPLEXES, AND METHODS OF USE THEREOF MOLECULAR INSIGHT PHARM INC (US) 2015-12-23 EP disclosed
US-20150246144-A1 LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) BIOLOGICAL EVALUATION, AND USE OF IMAGING AGENTS THE JOHNS HOPKINS UNIVERSITY (US) 2015-09-03 US disclosed
US-9044468-B2 Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents THE JOHNS HOPKINS UNIVERSITY (US) 2015-06-02 US disclosed
US-20090023787-A1 TECHNETIUM-DIPYRIDINE COMPLEXES, AND METHODS OF USE THEREOF MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2009-01-22 US disclosed
US-7381399-B2 Technetium-dipyridine complexes, and methods of use thereof MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2008-06-03 US disclosed
US-20080025915-A1 Technetium-And Rhenium-Bis (Heteroaryl) Complexes, And Methods Of Use Thereof CITIZENS BANK, N.A. 2008-01-31 US disclosed
EP-1713515-A1 TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES, AND METHODS OF USE THEREOF Molecular Insight Pharmaceuticals, Inc. (US) 2006-10-25 EP disclosed
EP-1482985-A4 TECHNETIUM-DIPYRIDINE COMPLEXES, AND METHODS OF USE THEREOF MOLECULAR INSIGHT PHARM INC (US) 2006-06-28 EP disclosed
US-20060034758-A1 Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2006-02-16 US disclosed
WO-2005079865-A1 TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES, AND METHODS OF USE THEREOF MOLECULAR INSIGHT PHARMACEUTICALS (US) 2005-09-01 WO disclosed
EP-1482985-A2 TECHNETIUM-DIPYRIDINE COMPLEXES, AND METHODS OF USE THEREOF Biostream, Inc. (US) 2004-12-08 EP disclosed
US-20030235843-A1 Technetium-depyridine complexes, and methods of use thereof CITIZENS BANK, N.A. 2003-12-25 US disclosed
WO-2003077727-A2 TECHNETIUM-DIPYRIDINE COMPLEXES, AND METHODS OF USE THEREOF BIOSTREAM, INC. (US) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180085478-A1 LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) BIOLOGICAL EVALUATION, AND USE OF IMAGING AGENTS FOLH1, KLK3, PHOSPHO1 SMN1; SMN2 4613/4885TDP1 3381/4885MAPT 1350/4885
US-20220299521-A1 CHEMOSELECTIVE SENSITIVITY BOOSTER FOR TAGGING A PEPTIDE, PEPTIDE CONJUGATE, OR SIMILAR REACTIVE MOLECULE PTMS, PA2G4, MAX SMN1; SMN2 3108/4885TDP1 4554/4885MAPT 3491/4885
US-20030235843-A1 Technetium-depyridine complexes, and methods of use thereof SLC7A5, DNPEP, SLC7A1 SMN1; SMN2 4210/4885TDP1 808/4885MAPT 2801/4885
US-10039845-B2 Labeled inhibitors of prostate specific membrane antigen (PSMA) biological evaluation, and use of imaging agents FOLH1, KLK3, PHOSPHO1 SMN1; SMN2 4613/4885TDP1 3381/4885MAPT 1350/4885
US-20150246144-A1 LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) BIOLOGICAL EVALUATION, AND USE OF IMAGING AGENTS FOLH1, KLK3, PHOSPHO1 SMN1; SMN2 4613/4885TDP1 3381/4885MAPT 1350/4885
US-20060034758-A1 Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof SLC7A5, RAB35, AADAT SMN1; SMN2 4259/4885TDP1 2995/4885MAPT 3876/4885
US-12625144-B2 Chemoselective sensitivity booster for tagging a peptide, peptide conjugate, or similar reactive molecule DPYSL3, CD2BP2, PTMS SMN1; SMN2 3324/4885TDP1 2841/4885MAPT 3019/4885
US-20090023787-A1 TECHNETIUM-DIPYRIDINE COMPLEXES, AND METHODS OF USE THEREOF SLC7A5, SLC7A1, AADAT SMN1; SMN2 4102/4885TDP1 1026/4885MAPT 2979/4885
US-20080025915-A1 Technetium-And Rhenium-Bis (Heteroaryl) Complexes, And Methods Of Use Thereof SLC7A5, RAB35, AADAT SMN1; SMN2 4259/4885TDP1 2995/4885MAPT 3876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.